Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Mediastinal B Cell Lymphoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	IMPT-314 Sensitive: B - Late Trials PRNewswire - 2 weeks (New B) IMPT-314 Sensitive : B PRNewswire - 2wk	IMPT-314 Sensitive: B - Late Trials PRNewswire - 2 weeks IMPT-314 Sensitive : B PRNewswire - 2 weeks - (New B)
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks (New A1) lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3wk	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
MYC overexpression	Mediastinal B Cell Lymphoma	MYC overexpression	Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3
EZH2 overexpression	Mediastinal B Cell Lymphoma	EZH2 overexpression	Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3
MYC rearrangement	Mediastinal B Cell Lymphoma	MYC rearrangement	Mediastinal B Cell Lymphoma	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3
BCL6 rearrangement	Mediastinal B Cell Lymphoma	BCL6 rearrangement	Mediastinal B Cell Lymphoma	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3